Law360, New York (September 18, 2006, 12:00 AM EDT) -- Marking a victory for Barr Pharmaceuticals Inc. in a long-running case over authorized generics, the U.S. Court of Appeals for the Second Circuit has denied a bid for rehearing by a group of consumers in the Tamoxifen Citrate antitrust lawsuits.
Barr, the defendant in the class actions, along with AstraZeneca Pharmaceuticals, said on Monday that the plaintiffs' petitions for rehearing and rehearing en banc were denied on Sept. 15, ending the litigation before the Second Circuit.
"The court's denial of the rehearing petitions re-enforces the growing...
In Win For Barr, Court Denies Tamoxifen Rehearing
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
